Number and per cent of subjects achieving a target IOP of ≤17, ≤16 and ≤15 mm Hg on day 29 (PPS)
| Number (per cent) of subjects achieving target response | ||||||
|---|---|---|---|---|---|---|
| Target IOP, mm Hg | 08:00 | 10:00 | 12:00 | 16:00 | 20:00 | |
| ≤17 | ONO-9054 Xalatan | 21 (39.6) 23 (39.7) | 29 (54.7) 24 (41.4) | 26 (49.1) 27 (46.6) | 33 (62.3) 31 (53.4) | 31 (58.5) 24 (41.4) |
| ≤16 | ONO-9054 Xalatan | 14 (26.4) 15 (25.9) | 23 (43.4) 17 (29.3) | 21 (39.6) 17 (29.3) | 25 (47.2) 17 (29.3) | 27 (50.9) 16 (27.6) |
| ≤15* | ONO-9054 Xalatan | 7 (13.2) 7 (12.1) | 17 (32.1) 9 (15.5) | 17 (32.1) 10 (17.2) | 18 (34.0) 6 (10.3) | 22 (41.5) 10 (17.2) |
Data are mean±SD. The percentage of subjects achieving target IOP on Day 29 (≤17, ≤16 and ≤15 mmHg) was greater for ONO-9054 than Xalatan, and the odds of achieving a target IOP ≤15 mmHg for ONO-9054 were 2.4 times more than the odds for Xalatan (*p<0.01, post hoc analysis; ≤17 and ≤16 analyses not performed).
IOP, intraocular pressure; PPS, per protocol set.